KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $99.3 million.

  • Ionis Pharmaceuticals' Accumulated Expenses fell 20.17% to $99.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.3 million, marking a year-over-year decrease of 20.17%. This contributed to the annual value of $108.4 million for FY2024, which is 26.68% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Accumulated Expenses stood at $99.3 million, which was up 0.36% from $99.0 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Accumulated Expenses peaked at $147.9 million during Q4 2023, and registered a low of $75.2 million during Q2 2021.
  • In the last 3 years, Ionis Pharmaceuticals' Accumulated Expenses had a median value of $108.4 million in 2024 and averaged $112.6 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 78.76% in 2022, then decreased by 26.68% in 2024.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Accumulated Expenses stood at $88.6 million in 2021, then spiked by 58.20% to $140.1 million in 2022, then climbed by 5.56% to $147.9 million in 2023, then declined by 26.68% to $108.4 million in 2024, then fell by 20.17% to $99.3 million in 2025.
  • Its last three reported values are $99.3 million in Q3 2025, $99.0 million for Q2 2025, and $102.7 million during Q1 2025.